ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Travere Therapeutics, Inc. ?
1
With a growth in Net Sales of 19.03%, the company declared Outstanding results in Dec 25
- The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 37.79 MM
- NET PROFIT(HY) Higher at USD 3.72 MM
- ROCE(HY) Highest at -57.8%
2
Market Beating Performance
- The stock has generated a return of 35.28% in the last 1 year, much higher than market (S&P 500) returns of 14.90%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Travere Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Travere Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Travere Therapeutics, Inc.
39.87%
3.94
68.33%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.87%
EBIT Growth (5y)
3.13%
EBIT to Interest (avg)
-17.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.91
Sales to Capital Employed (avg)
0.63
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
22.52
EV to EBIT
-41.07
EV to EBITDA
-1241.74
EV to Capital Employed
23.54
EV to Sales
5.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-57.30%
ROE (Latest)
-43.77%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 37.79 MM
NET PROFIT(HY)
Higher at USD 3.72 MM
ROCE(HY)
Highest at -57.8%
RAW MATERIAL COST(Y)
Fallen by -4.57% (YoY
NET SALES(Q)
At USD 129.69 MM has Grown at 19.03%
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 577.33 MM
Here's what is working for Travere Therapeutics, Inc.
Net Profit
At USD 3.72 MM has Grown at 103.28%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 37.79 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD 3.72 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Sales
At USD 129.69 MM has Grown at 19.03%
over average net sales of the previous four periods of USD 108.96 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Raw Material Cost
Fallen by -4.57% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 18.14 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Travere Therapeutics, Inc.
Cash and Eqv
Lowest at USD 577.33 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
